Related Experiment Video
Updated: Jul 14, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Vita Genomics, Inc
Lawrence Shih-Hsin Wu1, Chun-Lin Su, Ellson Chen
1Vita Genomics, Inc., 7Fl. No.6, Sec.1, Jungshing Rd., Wugu Shiang, Taipei, 248 Taiwan. ellson.chen@vitagenomics.com
Abstract:
Vita Genomics, Inc., centered in Taiwan and China, aims to be a premier genomics-based biotechnological and biopharmaceutical company in the Asia-Pacific region. The company focuses on conducting pharmacogenomics research, in vitro diagnosis product development and specialty contract research services in both genomics and pharmacogenomics fields. We are now initiating a drug rescue program designed to resurrect drugs that have failed in the previous clinical trials owing to low efficacies. This program applies pharmacogenomics approaches using biomarkers to screen subsets of patients who may respond better or avoid adverse responses to the test drugs. Vita Genomics, Inc. has envisioned itself as an important player in the healthcare industry offering advanced molecular diagnostic products and services, revolutionizing thedrug-development process and providing pharmacogenomic solutions.
Related Concept Videos
Genomics
DNA Microarrays
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Genetic Lingo
In-vitro Mutagenesis
